SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001636050-19-000070
Filing Date
2019-08-09
Accepted
2019-08-09 07:03:03
Documents
3
Period of Report
2019-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K axovant0809198k.htm 8-K 39305
2 EXHIBIT 99.1 exhibit991.htm EX-99.1 96691
3 image.jpg GRAPHIC 5086
  Complete submission text file 0001636050-19-000070.txt   144538
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37418 | Film No.: 191011283
SIC: 2834 Pharmaceutical Preparations